Patent · US Active

Treatment of cancer involving mutated KRAS or BRAF genes

US8932588B2 · kind B2 · utility

0Cited by

14References

12Claims

0Family size

Assignee

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · AU

Inventors

Norbert Kienzle · Parramatta, AU
Anthony G. Doyle · Chatswood, AU
Tony Rowe · Teddington, GB

Key dates

Filing date	Oct 29, 2010
Grant date	Jan 13, 2015
Priority date	—
Expiry date	Oct 29, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/732
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.